Urolithin A Supplementation in Middle-aged Adults With Obesity

Last updated: June 25, 2025
Sponsor: University of Oklahoma
Overall Status: Completed

Phase

N/A

Condition

Dementia

Vascular Diseases

Alzheimer's Disease

Treatment

Placebo

Urolithin A

Clinical Study ID

NCT05921266
UA15561
  • Ages 40-64
  • All Genders

Study Summary

The goal of this clinical trial is to learn about the effect of urolithin A, a dietary supplement, on blood flow in middle-aged adults with obesity. The main question it aims to answer is:

  • Does urolithin A supplementation improve blood flow in large and small blood vessels in middle-aged adults with obesity?

Participants will be asked to:

  • Take the dietary supplement daily for 4 weeks

  • Attend two study visits to have their blood vessels checked, answer questionnaires, and give a sample of blood

Researchers will compare people who took the dietary supplement with others who took a placebo to see if the blood flow in the blood vessels improved.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age: 40-64 years old, inclusive

  • Obesity [BMI ≥30 kg/m2]

  • Ability to read, write, and speak English

  • Competence to provide written informed consent

Exclusion

Exclusion Criteria:

  • Pregnant or breastfeeding women, or women who intend to become pregnant within thestudy period

  • History of uncontrolled hypertension

  • History of uncontrolled type 1 or type 2 diabetes mellitus

  • Significant cardiac disease or chest pain in the last 6 months

  • History of untreated depression or anxiety

  • History of cognitive impairment

  • History of uncontrolled significant GI disease (e.g., IBS, Crohn's disease)

  • Allergy or intolerance to one or more of the intervention components

  • Undergoing treatment for active cancer

  • History of neurodegenerative disorders (e.g., multiple sclerosis)

  • Presence of any condition affecting swallowing ability

  • Any other medical condition that the investigators deem would adversely affect theparticipant's safety or ability to complete the study

Study Design

Total Participants: 50
Treatment Group(s): 2
Primary Treatment: Placebo
Phase:
Study Start date:
October 02, 2023
Estimated Completion Date:
May 14, 2025

Study Description

This study aims to measure the effect of urolithin A supplementation on endothelial function, cerebral blood flow regulation, and serum biomarkers of NO bioavailability and mitochondrial function in middle-aged adults with obesity. Briefly, 54 adults aged 40-64 years of age with a body mass index equal to or greater than 30 kg/m2 will be recruited to participate in a double-blind placebo-controlled parallel study for 4 weeks. Participants will be randomly assigned to intervention or control group. Those in the intervention group will consume 1,000 mg of urolithin A daily in the form of softgel capsules, whereas those in the control group will consume a placebo. Data collection will occur at baseline (day 0) and endpoint (day 28). The investigators will compare outcomes between control and intervention group. Researchers expect that urolithin A supplementation in middle-aged adults with obesity improves endothelial function and cerebral blood flow regulation, and that this improvement is accompanied by changes in biomarkers of NO bioavailability and mitochondrial function.

Connect with a study center

  • Translational GeroScience Laboratory - O'Donoghue Research Building

    Oklahoma City, Oklahoma 73117
    United States

    Site Not Available

  • Translational GeroScience Laboratory - O'Donoghue Reserach Building

    Oklahoma City, Oklahoma 73117
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.